InvestSMART

Immutep Limited (ASX: IMM) - Announcements

Current share price for IMM : $0.048 0.001 (2.13%)+

ASX company news and announcements for Immutep Limited (IMM) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Immutep Limited (IMM) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Immutep Limited (IMM), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Immutep Limited (IMM)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$71 Application for quotation of securities - IMM 1 Oct 2024 12:42PM $0.328 $0.048 fallen by 85.34%
$71 Ceasing to be a substantial holder 26 Sep 2024 7:00PM $0.345 $0.048 fallen by 86.09%
$71 Change in substantial holding from IFL 25 Sep 2024 3:29PM $0.338 $0.048 fallen by 85.78%
$71 Change in substantial holding 24 Sep 2024 4:39PM $0.340 $0.048 fallen by 85.88%
$71 Immutep receives A$3.6 million French R&D Tax Incentive 24 Sep 2024 8:29AM $0.345 $0.048 fallen by 86.09%
$71 Change of Director's Interest Notice - M Voigt 19 Sep 2024 9:55AM $0.345 $0.048 fallen by 86.09%
$71 Data to be presented from Ph II trial in Soft Tissue Sarcoma 18 Sep 2024 8:32AM $0.340 $0.048 fallen by 85.88%
$71 New Positive Efficacy Data for Efti in Head and Neck Cancer 16 Sep 2024 8:30AM $0.400 $0.048 fallen by 88%
$71 Becoming a substantial holder 12 Sep 2024 6:55PM $0.405 $0.048 fallen by 88.15%
$71 S&P DJI Announces September 2024 Quarterly Rebalance 6 Sep 2024 5:10PM $0.390 $0.048 fallen by 87.69%
$71 Appendix 4E & 2024 Full Year Statutory Accounts 30 Aug 2024 9:55AM $0.388 $0.048 fallen by 87.61%
$71 Immutep Corporate Presentation 21 Aug 2024 9:26AM $0.350 $0.048 fallen by 86.29%
$71 TACTI-003 data selected for oral presentation at ESMO 2024 20 Aug 2024 9:50AM $0.355 $0.048 fallen by 86.48%
$71 First Participant Dosed in Phase I Study of IMP761 14 Aug 2024 8:19AM $0.310 $0.048 fallen by 84.52%
$71 Immutep to Participate in Upcoming Investor Conferences 7 Aug 2024 9:12AM $0.290 $0.048 fallen by 83.45%
$71 Immutep Quarterly Activities Report and Appendix 4C 31 Jul 2024 9:28AM $0.338 $0.048 fallen by 85.78%
$71 Change in substantial holding 26 Jul 2024 4:43PM $0.340 $0.048 fallen by 85.88%
$71 Successful Meeting with FDA on Phase III Design in NSCLC 22 Jul 2024 8:12AM $0.295 $0.048 fallen by 83.73%
$71 Regulatory Clearance received for Phase 1 trial of IMP761 17 Jul 2024 8:48AM $0.300 $0.048 fallen by 84%
$71 Becoming a substantial holder 12 Jul 2024 3:51PM $0.360 $0.048 fallen by 86.67%
$71 Positive results in TACTI-003 for 1L HNSCC cohort B patients 12 Jul 2024 8:26AM $0.295 $0.048 fallen by 83.73%
$71 Webcast to discuss data presented at ESMO Plenary Session 12 Jul 2024 8:26AM $0.295 $0.048 fallen by 83.73%
$71 Change in substantial holding 4 Jul 2024 8:16AM n/a $0.048 n/a
$71 Details for Immutep Webcast & ESMO Virtual Plenary Session 3 Jul 2024 8:33AM n/a $0.048 n/a
$71 Webcast slides for new Efti clinical data in 1st line HNSCC 27 Jun 2024 8:31AM $0.435 $0.048 fallen by 88.97%

151 - 175 of 778 results

Page 7 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.